ArticleInternational journal of nanomedicine2017
Surface-modified gatifloxacin nanoparticles with potential for treating central nervous system tuberculosis.
Article in International journal of nanomedicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.
- Nanoparticles and nanoformulated drugs as promising delivery system in treatment of microbial-induced CNS infection: a systematic review of literature.Journal of neurovirology · 2021Pooled it
- Angiopep-2 Modified Exosomes Load Rifampicin with Potential for Treating Central Nervous System Tuberculosis.International journal of nanomedicine · 2023Article
- Antiparkinsonian Agents in Investigational Polymeric Micro- and Nano-Systems.Pharmaceutics · 2022Review
- Functionalization of Morin-Loaded PLGA Nanoparticles with Phenylalanine Dipeptide Targeting the Brain.Pharmaceutics · 2022Article
- Micro- and Nano-Systems Developed for Tolcapone in Parkinson's Disease.Pharmaceutics · 2022Article
- Novel mesoporous silica nanocarriers containing gold; a rapid diagnostic tool for tuberculosis.BMC complementary medicine and therapies · 2021Article
- Effects of bee venom and dopamine-loaded nanoparticles on reserpine-induced Parkinson's disease rat model.Scientific reports · 2021Article
- The Application of Nanotechnology for the Diagnosis and Treatment of Brain Diseases and Disorders.Frontiers in bioengineering and biotechnology · 2021Review
- From adsorption to covalent bonding: Apolipoprotein E functionalization of polymeric nanoparticles for drug delivery across the blood-brain barrier.Advanced therapeutics · 2021Article
- Nano-based anti-tubercular drug delivery: an emerging paradigm for improved therapeutic intervention.Drug delivery and translational research · 2020Review
- PLGA Nanoparticles for the Intraperitoneal Administration of CBD in the Treatment of Ovarian Cancer: In Vitro and In Ovo Assessment.Pharmaceutics · 2020Article
- Impact of nanoparticles on neuron biology: current research trends.International journal of nanomedicine · 2018Review
- Nanotechnology-based drug delivery of ropinirole for Parkinson's disease.Drug delivery · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A new nanocarrier is developed for the passage of gatifloxacin through the blood-brain barrier to treat central nervous system tuberculosis. Gatifloxacin nanoparticles were prepared by nanoprecipitation using poly(lactic-
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.